Justin Gover serves on the boards of Xenon Pharmaceuticals (Nasdaq: XENE), Compass Pathways (Nasdaq: CMPS), Aeovian Pharmaceuticals, Rady Children’s Institute for Genomic Medicine and CURE Epilepsy. Mr. Gover was the Founding Chief Executive Officer of GW Pharmaceuticals, leading the company for more than two decades from inception through its $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW became a fully integrated global biotech and successfully commercialized Epidiolex® (cannabidiol), the first plant-derived cannabis-based medicine approved in the U.S. and Europe for childhood-onset epilepsies. He holds an M.B.A. from INSEAD and a B.Sc. (Hons) from Bristol University.